Introduction: Allogeneic transplantation is the only curative option for patients with high risk hematologic malignancies. Only one third of them have an HLA identical sibling donor and around 60-70% will find an unrelated donor, that's why HAPLO-HSCT offers a therapeutic option to most of these patients with the advantages of quick availability, easy programation and logistics, and a committed donor. Bone marrow (BM) or peripheral blood stem cells (PBSC) could be used as graft source but it's not established if any of them offer significant advantages. Patients and Methods: We retrospectively evaluated the results of HAPLO-HSCT with reduced conditioning regimens and GVHD prophylaxis based on PT-CY (50 mg/kg on days +3 and +4) and a calcineurin inhibitor plus mycophenolate from day +5 performed in GETH centers, with focus on the graft source. Results: From Dec-2007, 118 HAPLO-HSCT have been done in 17 centers. Median age was 36 years (16-67), 64% were males and all were in advanced phases of their disease or presented high risk features (Hodgkin's 43%, AML/ALL/MDS 36%, NHL/ myeloma/others 21%). Previous HSCT had been employed in 64% (autologous 66, allogeneic 19), and in 36% the HAPLO-HSCT was their first transplant. Disease status at HAPLO-HSCT was CR in 44%, with persistent disease in 55%. BM was the graft source in 48 patients (41%) and PBSC in 70 (59%), non T-cell depleted in all cases. The haploidentical donor was the patient's mother (28%), father (10%), siblings (44%) or offspring (18%). Baltimore's reduced conditioning (RIC) including 200cGy was employed in 15% and RIC based on IV busulfan in 85% (44% with 3.2 mg/kg on day -2 (BUX1), and days -3 and -2 (BUX2) in 41%). Median neutrophils engraftment was reached at day +18 (13-45) and platelets >20K at day +26 (11-150), without significant differences (NS) between BM and PBSC.
Main toxic complications were grade II-III mucositis in 36%, febrile neutropenia in 75% and CMV reactivations in 62%. Transplant related mortality rate (TRM) at 1 year was 19% with BM vs 23% with PBSC (NS). Day +100 grade II-IV acute GVHD cumulative incidence (CI) was 46% vs 48%, and grade III-IV was 15% and 10% with BM and PBSC respectively. Chronic GVHD CI at 1 year was 40% vs 24% (NS), being extensive in 16% and 9% (NS) respectively. No differences in acute or chronic GvHD CI were seen when comparing BM against PBSC. After a median follow-up of 10 months (3-61), estimated event-free survival (EFS) and overall survival (OS) at 18 months were 41% and 59% respectively. CI of relapse or progression was 29%. No significant differences in TRM, EFS, OS and relapse incidence were detected between BM and PBSC. Conclusions: HAPLO-HSCT with PT-CY in the treatment of high risk hematologic malignancies, offers long-lasting remissions with manageable toxicity and GVHD, employing either BM or PBSC that render similar results as graft source. Patients and Methods: This is a retrospective analysis of patients with thalassaemia major who underwent allogeneic stem cell transplantation at CMC Hospital, Vellore India between November 2009 and December 2013 using a uniform Fludarabine/Treosulfan/Thiotepa based conditioning regimen. Graft source was either unmanipulated bone marrow or G-CSF primed peripheral blood stem cells (PBSC). Donors were either HLA identical sibling/family or unrelated donors. Whole blood chimerism was performed using VNTRs on Day 30, 60-90, and subsequently based upon physician decision. >95% donor cells was considered as complete chimerism. If there was a drop in chimerism, reduction of immunosuppression and donor lymphocyte infusion (DLI) was considered. Results: 132 patients underwent HSCT for thalassemia major during this period of which 120 who survived more than 4 weeks post HSCT were evaluable for chimerism. There were 70 males and 50 females with a median age was 9.3 years (range: 3 e 21). Majority had Lucarelli Class III thalassaemia. 113 (94.1%) had matched sibling or family donors while 7 had unrelated donors. Graft source was predominantly PBSC in 97 (80.8%). At day 28 post HSCT, 97 (80.8%) had complete chimerism (CC) while graft rejection occurred in 3 and 20 (16.6%) had mixed chimerism (MC) (Level 1 in 12, level 2 and level 3 had 4 each). Of the 97 patients with CC, 23 (23.7%) developed mixed chimerism between 2-4 months after HSCT. This included level 1 MC in 14, level 2 MC in 7 and level 3 MC in 2. The overall incidence of MC occurring at any time post HSCT was 35.8%. Tapering and cessation of cyclosporine was done in all patients and 5 patients had 1-3 courses of DLI. On follow up of the 43 patients with MC, 24 achieved complete chimerism, 10 had stable mixed chimerism and 9 had rejection (mostly level 3 MC). Two patients developed mild graft versus host disease after DLI. Conclusion: Occurrence of mixed chimerism is common after allogeneic HSCT for thalassaemia after Fludarabine/ Treosulfan/Thiotepa conditioning. Rapid tapering of immunosuppression and judicious use of DLI helps in reducing the risk of secondary graft rejection. Closer monitoring of chimerism after HSCT needs to be done when such conditioning regimens are used. Objectives: To assess the effects of additional consolidation therapy in acute myeloid leukemia (AML) patients before allogeneic hematopoietic stem cell transplantation (HSCT). Methods: Seventy-two AML patients (range: 18-55 years) who transplanted in CR1 after being treated with a standard chemotherapy (7+3) regimen were randomly divided into two groups. Thirty-six patients in group A directly underwent transplantation and 36 in group B received chemotherapy regimen (5+2) prior to allogeneic HSCT. All patients received fully HLA-matched transplants. Results: The median age at transplantation was 38.3 in group A and 37.2 in group B. The male to female ratio was 21:15 and 23:13 in groups A and B, respectively. The median time to neutrophil and platelet recovery was 8 and 27 days in group A, while it was 9 and 19 days in group B, respectively (P: 0.77, 0.01). Acute graft-versus-host disease (GvHD) was more frequent in group A (26 vs. 23) patients(P:0.44). Chronic 
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